C. Light Technologies uses AI to diagnose Alzheimer’s through retinal eye studies
Summary
The company received this investment via ADDF’s Diagnostics Accelerator, a collaborative research initiative supported by Leonard A. Lauder, Bill Gates, the Dolby family, the Charles and Helen Schwab Foundation, Jeff Bezos, and MacKenzie Scott, among others. This new investment will fund a novel pilot study with the University of California at San Francisco Memory and Aging Center to look at changes in fixational eye motion during the earliest stage of Alzheimer’s disease, generally known as mild cognitive impairment. While C. Light is looking for automating the diagnosis, current methods are a lot more labor intensive, as doctors and other specialists have to evaluate patients with manual testing. Part of the reason for the slow progress is that drug developers haven’t had viable biomarkers they can use to effectively stratify patients and track disease on a fine scale. She said the company’s growing databases and accompanying AI can change the way we monitor and treat neurological disease for future generations.